Jefferies Maintains Buy on St. Jude Medical (STJ)

Jefferies is out with its report today on St. Jude Medical STJ, maintaining Buy. In a note to clients, Jefferies writes, "New product flow and the momentum from the ICD generator replacement cycle tailwind should fuel market share growth for STJ in the near-term. Portfolio diversification into new, underpenetrated markets should serve as growth drivers well into the future. At just 13x 2012 earnings, the stock could trade to $49 over the coming year, which is our current price target. We continue to rate shares Buy." Shares of STJ closed Friday at $41.96.